Rifampicin - GeneCare Research

Drug Profile

Rifampicin - GeneCare Research

Alternative Names: GK-001

Latest Information Update: 25 Apr 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator GeneCare Research Institute
  • Class Antibacterials; Antineoplastics; Antituberculars; Hepatoprotectants; Rifamycins
  • Mechanism of Action Angiogenesis inhibitors; Oxidoreductase inhibitors; Transaminase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase III Liver cancer

Most Recent Events

  • 31 Mar 2017 GeneCare Research Institute completes two phase-III trials in liver cancer (prevention of recurrence in patients with chronic hepatitis) in Japan (UMIN000007667; UMIN000007668)
  • 15 Mar 2016 Rifampicin is still in phase III trials for liver cancer (Prevention of recurrence in patients with chronic hepatitis) in Japan (PO)
  • 15 Mar 2016 No recent reports on development identified - Phase-II for liver cancer (Prevention) in France and Spain (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top